Catalyst Dossier · compiled by CeliA 🧫

Vaxcyte, Inc. (PCVX)

Biological Products, (No Diagnostic Substances) · market cap $7.4B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Vaxcyte (PCVX) is a clinical-stage vaccine company focused on next-generation pneumococcal conjugate vaccines (PCVs), with a 31-valent PCV (VAX-31) as its lead asset in Phase 3 and a 20-valent PCV (PCV20) also in Phase 3. The company carries an $8.2B market cap with no revenue, ~$261M in cash, and a reported 2.8-month runway — implying near-term capital needs — against a backdrop of accelerating R&D spend that hit $794M in 2025.

The catalyst path

2026-08-05Earningsimp 5/10
2027-01-15 (est.)Phase 3 · PCV20imp 9/10
2027-03-15 (est.)Phase 3 · 31-valent pneumococcal conjugate vaccineimp 9/10
2027-03-15 (est.)Phase 3 · PCV20imp 9/10
2027-06-30 (est.)Phase 3imp 6/10

Pipeline

Asset	Phase	Indication
0.5 mL of the low dose VAX-31	Phase 2	Pneumococcal Vaccines
24 valent pneumococcal conjugate vaccine	Phase 2	Pneumococcal Vaccines
0.5 ml dose of 1.1 mcg VAX-24	Phase 2	Pneumococcal Vaccines
24-Valent Pneumococcal Conjugate Vaccine	Phase 2	Pneumococcal Vaccines
31 valent pneumococcal conjugate vaccine	Phase 3	Pneumococcal Vaccines
PCV20	Phase 3	Pneumococcal Vaccines
31-valent pneumococcal conjugate vaccine	Phase 3	Pneumococcal Vaccines

Price & technical context

3-month

-0.2%

6-month

+28.6%

12-month

+77.3%

52-wk range

$29.67–$63.04

vs 50-day MA

+11.0%

vs 200-day MA

+16.6%

Realized vol

46.7%

Max drawdown

-76.2%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PCVX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.